IRCT20130812014333N171 IRCT 2021-07-04 Kermanshah University of Medical Sciences Effect of L Carnitine on severity of uremic restless legs syndrome Study the effect of treatment with L Carnitine on severity of uremic restless legs syndrome in dialysis patients 2021-05-21 anticipated 82 Complete https://irct.ir/trial/56160 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple random method. 82 cards are selected and numbers from 1-82 are inserted on the cards. The cards are placed in an envelope. Two of the design partners take one card out of the envelope each time and announce the card number. Paired numbers are assigned to the intervention group and odd numbers to the control group, Blinding description: Drugs can only be identified by the serial number on the container. The serials are with the main researcher and will remain confidential until the end of the study. The clinician will not be aware of assigning individuals to study groups. The person evaluating the patients will also not know about the assignment. In fact, clinicians and outcome assessors are unaware of who is receiving the new drug. Therefore, this study will be double-blinded. 2-3 Restless leg syndrome. Intervention 1: The intervention group will receive 500 mg of L-carnitine tablets (Behta) daily, every 12 hours for three months. Intervention 2: The control group will receive a 500 mg daily placebo (in pill form and Amin Pharmaceutical Company) every 12 hours for 3 months. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information